Treats major depressive disorder (MDD). ANDA 203013, held by Alembic. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 203013 (Bupropion Hydrochloride), held by Alembic, was first approved by FDA on Jun 8, 2018, with 6 approved supplements and 0 published complete response letters.
Bupropion hydrochloride tablets USP are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion hydrochloride tablets USP in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2018 | Original application | Approved | None posted |
| Bupropion Hydrochloride75MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride100MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Nov 6, 2025 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jan 29, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 3, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 3, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 3, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 8, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters